About Acurx Pharmaceuticals, Inc.
https://www.acurxpharma.comAcurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections.
CEO
David P. Luci CPA,
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-08-05 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
ARMISTICE CAPITAL, LLC
Shares:1.08M
Value:$2.96M
BLACKROCK INC.
Shares:27.5K
Value:$75.36K
ADVISOR GROUP HOLDINGS, INC.
Shares:7.58K
Value:$20.77K
Summary
Showing Top 3 of 6
About Acurx Pharmaceuticals, Inc.
https://www.acurxpharma.comAcurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $2.03M ▼ | $-1.99M ▲ | 0% | $-1.23 ▲ | $-1.99M ▲ |
| Q2-2025 | $0 | $2.27M ▲ | $-2.25M ▼ | 0% | $-1.89 ▲ | $-2.27M ▼ |
| Q1-2025 | $0 | $2.15M ▼ | $-2.15M ▲ | 0% | $-2.14 ▲ | $0 |
| Q4-2024 | $0 | $2.78M ▼ | $-2.78M ▲ | 0% | $-3.27 ▲ | $0 |
| Q3-2024 | $0 | $2.82M | $-2.82M | 0% | $-3.45 | $0 |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $5.91B ▲ | $6.11B ▲ | $2.47B ▲ | $3.64B ▲ |
| Q2-2025 | $6.06M ▲ | $6.16M ▲ | $2.59M ▲ | $3.57M ▲ |
| Q1-2025 | $4.64M ▲ | $4.81M ▲ | $2.49M ▼ | $2.31M ▲ |
| Q4-2024 | $3.71M ▼ | $3.86M ▼ | $3.24M ▼ | $615.12K ▼ |
| Q3-2024 | $5.76M | $5.98M | $3.32M | $2.66M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.99M ▲ | $-1.88M ▼ | $0 | $1.72M ▼ | $-157.33K ▼ | $-1.88M ▼ |
| Q2-2025 | $-2.25M ▼ | $-1.67M ▲ | $0 | $3.09M ▲ | $1.42M ▲ | $-1.67M ▲ |
| Q1-2025 | $-2.15M ▲ | $-2.05M ▲ | $0 | $2.99M ▲ | $937.17K ▲ | $-2.05M ▲ |
| Q4-2024 | $-2.78M ▲ | $-2.25M ▼ | $0 | $194.55K ▼ | $-2.06M ▼ | $-2.25M ▼ |
| Q3-2024 | $-2.82M | $-2.19M | $0 | $1.59M | $-598.29K | $-2.19M |
CEO
David P. Luci CPA,
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-08-05 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
ARMISTICE CAPITAL, LLC
Shares:1.08M
Value:$2.96M
BLACKROCK INC.
Shares:27.5K
Value:$75.36K
ADVISOR GROUP HOLDINGS, INC.
Shares:7.58K
Value:$20.77K
Summary
Showing Top 3 of 6